For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Plasma fibrinogen is a large hexamer glycoprotein (Mr=340,000), containing two sets of three different chains (?, ?, and ?). Synthesized in the liver and circulating at a concentration of around 2-4 mg/ml, it plays a role in blood clotting and inflammation. During normal blood coagulation, a cascade activates the prothrombin to convert soluble fibrinogen into insoluble fibrin strands. These strands are then cross-linked by factor XIII to form a blood clot. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, displaying vasoconstrictor and chemotactic activities. Many studies have shown that elevated fibrinogen is a major risk factor for atherosclerosis and associated with an increased risk of ischemic heart disease (IHD), stroke and other thromboembolism. Low plasma fibrinogen concentrations are associated with an increased risk of bleeding due to impaired primary and secondary hemostasis.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.